GTBP · Amended Quarterly Report (Form 10-Q/A) · Filed March 6, 2026

Gt Biopharma Inc — 10-Q/A exhibit

ex10-8.htm

Exhibit 10.8

FIRST AMENDMENT TO THE

RESEARCH AGREEMENT

THIS FIRST AMENDMENT is effective as of the June 18, 2025 (“First Amendment”) by and between Regents of the University of Minnesota (the “University”) and GT Biopharma, Inc. (the “Sponsor”).

WHEREAS, the parties entered into a Research Agreement dated July 1, 2023 (the “Agreement”); and

WHEREAS, the parties desire to amend the Agreement;

NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants contained herein, the parties agree as follows:

1.	The Expiration Date of the Agreement is December 31, 2025.

2.	The Contract Price is now One Million Nine Hundred Forty Thousand Six Hundred Eighty Six dollars ($1,940,686.00)

3.	The following is added to Article 4.2:

Sponsor shall make a payment of One Hundred Eight Thousand dollars ($108,000) on September 30, 2025. Sponsor shall make a final payment of One Hundred Eight Thousand dollars ($108,000) on December 31, 2025.

4.	Effect on Other Provisions. Except as expressly provided herein, all terms and conditions of the Agreement shall remain in full force and effect.

IN WITNESS WHEREOF, authorized representatives of the parties have executed this First Amendment on the date first above written.

REGENTS OF THE UNIVERSITY			GT BIOPHARMA INC.
OF MINNESOTA


By:			By:
Title:			Title:
Date:			Date:

Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer